Cell-Immune Pharma

Transforming Vaccine Design with T Cell Activation for Infectious Diseases and Virus-Induced Cancers.

Addressing virus variability with invariable epitopes and modular solutions for T cell control.

Cell-Immune Pharma pioneers a breakthrough in vaccine design by leveraging T-cell activation to combat virus variability. Our proprietary 3-step program delivers scalable solutions that enhance adaptability and durability in vaccine development.

T CellsRecognize and eliminate infected cells
Infected CellHijacked by the virus to replicate
VirusBuds from the cell and mutates to escape immunity

The Challenge

Viruses evolve.
Vaccines fall behind.

Rapid viral mutation leads to seasonal variability and immune escape. Current vaccines rely mainly on antibody-based immunity, which often falls against emerging strains.

Learn more about the challenge

Virus Evolution

High mutation rate leads to new variants and immune escape.

Stable Epitopes

Conserved regions remain unchanged across variants.

VS

Our Solution

Target what
doesn’t change.

We target conserved viral epitopes and activate T cells to deliver broad, durable, and long-term immune protection across variants and pathogens.

Discover our solution
“
The good thing about science is that it’s true whether or not you believe in it.
— Neil deGrasse Tyson

The Gap in Current Vaccines

In current vaccines, relevant targets are absent to trigger a powerful T cell response, so it’s mostly absent.

Antibody response (limited)
Antibodies block virus outside the cell
Virus mutates and escapes antibodies
Limited protection against new variants
T cell response (powerful & durable)
T cells recognize infected cells with conserved epitopes
T cells eliminate infected cells and stop viral replication
Long-lasting immunity and cross-variant protection
T cell immunity delivers what antibody-only vaccines can’t: broader coverage, longer protection, and real-world impact.

Our Platform

A 3-Step Proprietary Platform for Next-Generation Vaccines

We integrate natural immune recognition, biological validation, and modular vaccine design to identify the right targets and build vaccines that are adaptable, scalable, and built for the future.

How It Works
1

IDENTIFY

We identify invariable epitopes recognized by T cells in people with natural immunity.

2

VALIDATE

We validate targets using advanced assays and immune profiling technologies.

3

DESIGN

We design modular vaccine constructs to induce robust and lasting T cell responses.

Leadership

Experienced. Passionate. Committed.

Our team brings deep expertise in immunology, drug development, and biotechnology to advance the next generation of vaccines.

David Lapointe

David Lapointe

Chief Executive Officer

Dr. Réjean Lapointe

Dr. Réjean Lapointe, Ph.D.

Chief Scientific Officer
Co-founder

Dr. Jean-François Cailhier

Dr. Jean-François Cailhier, M.D. Ph.D.

Chief Medical Officer
Co-founder

Partner With Us

Let’s build the future of vaccines together.

We welcome collaborations, partnerships, and inquiries from organizations that share our mission.

Contact Us

Our Platform

A Smarter Way to
Design Better Vaccines

Our proprietary platform integrates natural immune recognition, biological validation, and modular design to create vaccines that are broader, more durable, and ready for tomorrow’s threats.

Our 3-Step Proprietary Program

From Natural Immunity to Better Vaccines

1

IDENTIFY

We identify invariable epitopes recognized by T cells in people with natural immunity.

  • Mining natural immune signatures
  • Advanced epitope prediction
  • Population coverage analysis
2

VALIDATE

We validate targets using advanced assays and immune profiling technologies.

  • T cell recognition assays
  • Multiplex T cell assays to capture breadth of potential protection
  • Functional validation
  • Immunogenicity profiling
3

DESIGN

We design modular vaccine constructs to induce robust and lasting T cell responses.

  • Modular antigen design
  • Optimized for breadth
  • Built for durability

Modular Vaccine Design

Built for Breadth.
Designed for Durability.

Our modular approach allows us to combine multiple validated T cell epitopes into a single vaccine construct, maximizing immune coverage across variants and populations.

Modular & Flexible

Easily adaptable to new variants and pathogens

Broad Population Coverage

Designed to cover diverse HLA types worldwide

Focus on T Cell Immunity

Activates both CD8+ cytotoxic and CD4+ helper T cells

Long-Lasting Protection

Targets conserved regions that don’t change

Modular Epitope Components

Modular Vaccine ConstructMultiple epitopes.
One powerful response.
Broad. Durable. Protective.
CD8+ T cell responseEliminates infected cells
CD4+ T cell responseCoordinates and amplifies immune protection

Our Differentiation

Why Our Platform Delivers More

We go beyond traditional approaches by focusing on what matters most: natural immunity, T cell activation, and conserved targets.

Cell-Immune PharmaCell-Immune PharmaTraditional VaccinesOther T Cell Approaches
Target TypeConserved, Invariable EpitopesVariable RegionsLimited Epitope Discovery
Immune FocusT Cell Immunity (CD4+ & CD8+)Antibody-FocusedT Cell Focused and Increased Antibody Production
CoverageBroad (Across Variants & Populations)Limited (Strain Specific)Variable
DurabilityLong-LastingOften Short-TermVariable
AdaptabilityModular & Rapidly AdaptableSlow to AdaptComplex / Non-Modular

Precision Vaccine Development:
From Natural Immunity to Next-Generation Vaccines

Study Natural Immunity

Analyze people who naturally cleared infections.

Identify T Cell Targets

Discover conserved epitopes recognized by T cells.

Validate & Confirm

Test and confirm protective immune responses.

Design Modular Vaccine

Combine epitopes into optimal vaccine constructs.

Induce Durable Protection

Generate strong, broad, and long-lasting T cell immunity.

A Platform Built for Today.
Ready for Tomorrow.

Our platform is built to stay ahead of evolving viruses and emerging threats by focusing on what doesn’t change: the power of T cell immunity.

Explore Our Science

Our Science

The Power of T Cells.
The Future of Vaccines.

T cells are central to immunity. Our science leverages natural T cell responses to build vaccines that are broader, longer lasting, and more resilient to viral change.

Why T Cells Matter

T Cells Provide the Protection Antibodies Alone Cannot

T cells work alongside antibodies to deliver complete and durable protection: clearing infected cells, coordinating immune responses, and providing long-term immune memory.

Direct Elimination of Infected Cells

CD8+ cytotoxic T cells kill virus-infected cells, reducing severity and transmission.

Coordinate the Immune Response

CD4+ helper T cells orchestrate stronger antibody production and activate other immune cells.

Target Intracellular Pathogens

T cells recognize and eliminate viruses hiding inside cells, where antibodies can’t reach.

Establish Immunological Memory

Memory T cells provide durable, long-term protection and rapid recall.

Balance the Immune Response

T cells help regulate immunity, preventing overbalance and immunopathology.

The T Cell Advantage

Virus infects
a cell
CD8+ T Cell
(cytotoxic)
CD4+ T Cell
(helper)
Infected cell
eliminated

T cells find and eliminate infected cells, stop viral replication, and build lasting immunity.

The Immune Response Explained

How T Cell Immunity Works

Our vaccines are designed to activate both CD8+ and CD4+ T cells by targeting conserved viral epitopes: regions of the virus that do not change over time.

Antibodies remain important, but antibody responses on their own are often far from optimal. CD4+ helper T cells strongly increase the production of neutralizing antibodies, so activating them also improves the antibody response.

1Antigen Presentation

Dendritic cells capture the vaccine antigen and present viral epitopes to T cells.

2T Cell Activation

CD4+ and CD8+ T cells are activated and expand.

3Effector Response

Activated CD8+ T cells eliminate infected cells, and CD4+ T cells help B cells produce neutralizing antibodies.

CD4+ help → ↑ neutralizing antibodies
4Memory Formation

Memory T cells remain ready for faster, stronger responses in the future.

Dendritic CellCD4+ T CellCD8+ T CellInfected CellB CellAntibodyViral Epitope

Scientific Validation

Built on Robust Science

We use advanced technologies and rigorous assays to identify, validate, and optimize protective T cell epitopes.

Epitope Discovery

High-throughput screening and immunoinformatics to identify conserved, immunogenic epitopes.

Immune Profiling

Deep profiling of T cell responses in diverse populations and HLA backgrounds.

Functional Assays

In vitro and ex vivo assays confirm cytotoxic potential, cytokine production, and polyfunctionality.

Structural Insight

Structural modeling ensures optimal epitope binding and cross-variant coverage.

Science drives everything we do.

We are advancing the next generation of vaccines by unlocking the full potential of T cell immunity.

Partner With Us

Contact Us

Let’s build the future
of T cell–driven vaccines.

We welcome collaborations, partnerships, and inquiries from investors, researchers, and organizations who share our mission to advance durable immunity and transform global health.

Illustration of a large virus particle surrounded by smaller particles

Get in Touch

Whether you’re interested in partnerships, investor relations, media, or general inquiries, we’d love to hear from you.

Our Offices

Cell-Immune Pharma Inc.

Montréal, Québec, Canada
Address to be provided soon.

Contact Our Team

Reach our leadership directly:

Interested in partnering with us?

We are actively exploring strategic collaborations to advance our programs and bring the next generation of vaccines to the world.

Partner With Us

About Us

Vaccines built on what
T cells actually see.

Cell-Immune Pharma is a Montréal biotechnology company developing next-generation antigens for T cell–driven vaccines against infectious diseases and virus-induced cancers.

Illustration of a cross-sectioned cell releasing virus particles

Our Story

More about us soon

The full story of Cell-Immune Pharma, its origins and its mission will be published here soon.